La chaîne d'options affiche les données clés des options sur actions de Altimmune à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Altimmune..

Altimmune (NASDAQ:ALT) Stock, Chaîne d'Options

ALTIMMUNE INC

Altimmune

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Altimmune Inc

AltLayer - United States Dollar

ALT11M2507 - United States Dollar

ALT11M250830 - United States Dollar

ALT11M251029 - United States Dollar

ALT2612 - United States Dollar

Morella Corp Ltd

ALPINE AUTO BROKERS INC by Alpine Auto Brokers Inc

Alpine Auto Brokers Inc

ALTURAS MINERALS CORP by Alturas Minerals Corp.

Alturas Minerals Corp

ALTITUDE INTL INC by Altitude International Holdings, Inc.

Altitude International Holdings Inc

Alta Equipment Group Inc. Class A Common Stock

Alta Equipment Group Inc

Alta Equipment Group Inc. Depositary Shares (each representing 1/1000th in a share of 10% Series A Cumulative Perpetual Preferred Stock)

ALTECH CHEMICALS LTD by Altech Chemicals Ltd.

Altech Batteries Ltd

AlTi Global Inc

Pacer Lunt Large Cap Alternator ETF

ARCADIUM LITHIUM PLC SHS

Kinetik Holdings Inc Warrants (09/11/2023)

ALTERNUS ENERGY GROUP PLC by ALTERNUS ENERGY GROUP PLC.

Alternus Energy Group PLC

Alto Ingredients Inc

ALTIPLANO METALS INC ORD by Altiplano Metals Inc.

Altiplano Metals Inc

ALTERA CORP COM

ALT5 Sigma Corp

Altitude Acquisition Corp Ordinary Shares - Class A

Altitude Acquisition Corp

Altitude Acquisition Corp Units (1 Ord Share Class A & 1/2 War)

Altitude Acquisition Corp Warrants (30/11/2027)

ALTEX INDUS INC by Altex Industries, Inc.

Altex Industries Inc

Global X Alternative Income ETF

Benzinga examined the prospects for <a href="http://www.benzinga.com/trading-ideas" target="_blank" rel="noreferrer noopener">many investors' favorite stocks</a> over the last week — here's a look at some of our top stories.
Wall Street surged this week as easing geopolitics and a potential pause in U.S.-China tariffs lifted sentiment. The S&amp;P 500 and Nasdaq hit record highs, boosted significantly by Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), whose stock jumped by about 10% to record its highest valuation — $3.8 trillion — overtaking Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) as the world's most valuable company
The tech rally reflected strong earnings from Nvidia's AI-centric chip business and supplier Micron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>), while broader market gains were bolstered by renewed risk appetite in equities.
Next week, investors will track the June jobs report, rhetoric on tariffs — including the July 8 "Liberation Day" deadline — and upcoming July 4 tax‑and‑spending legislative actions that could influence rates and yields.
Benzinga provides daily reports on the stocks most popular with investors. Here are a few of this past week's most bullish and bearish posts that are worth another look.

The Bulls
<a href="https://www.benzinga.com/markets/tech/25/06/46081553/nvidias-jensen-huang-sparks-quantum-stock-frenzy">"Nvidia's Big Moment Is Back—Stock Soared 500% The Last Time This Happened"</a>, by Piero Cingari, reports that Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) is forming a bullish golden cross — a 50-day moving average crossing above the 200‑day — after recovering from earlier tariff-induced weakness, which historically has preceded massive rallies, with gains as high as 800%, fueled by easing U.S.-China trade tensions and strong earnings.
<a href="https://www.benzinga.com/markets/earnings/25/06/46104401/micron-q3-earnings-revenue-eps-beat-estimates-data-center-revenue-guidance-ai-demand">"Micron Q3 earnings: Revenue, EPS beat estimates as data center revenue doubles, strong guidance on rising AI‑driven demand"</a>, by Adam Eckert, reports that Micron Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) delivered a strong Q3 with $9.3 billion in revenue (beating $8.87 billion estimates) and $1.91 adjusted EPS (versus $1.60 expected); data-center revenue more than doubled, and the company forecast Q4 revenue of $10.7 billion and EPS of $2.50 amid surging AI memory demand.
<a href="https://www.benzinga.com/trading-ideas/movers/25/06/46098312/palantir-stock-hits-all-time-high-whats-going-on">"Palantir stock hits all‑time high: what's going on?"</a>, by Adam Eckert, reports that Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) shares reached record highs — up roughly 500% over the past year and 93% year-to-date — driven by strong momentum (Benzinga Pro momentum score of 99), surging AI and government contracts including a $795 million U.S. Army deal, and positive Wall Street sentiment such as Loop Capital's raised price target.
For additional bullish calls of the past week, check out the following:
<a href="https://www.benzinga.com/markets/earnings/25/06/46084802/blackberry-stock-climbs-after-better-than-expected-q1-report-details">BlackBerry Stock Climbs After Better-Than-Expected Q1 Report: Details</a>
<a href="https://www.benzinga.com/markets/commodities/25/06/46120819/platinum-miners-forecasts-stocks">Platinum's Biggest Rally In 40 Years: These 6 Mining Stocks Could Be Top Gainers</a>
<a href="https://www.benzinga.com/trading-ideas/movers/25/06/46129177/pony-ai-stock-pops-on-report-uber-is-in-talks-with-travis-kalanick-to-invest-in-potential-deal">Pony AI Stock Pops On Report Uber Is In Talks With Travis Kalanick To Invest In Potential Deal</a>

The Bears
<a href="https://www.benzinga.com/trading-ideas/technicals/25/06/46080036/hims-crashes-on-novo-glp-1-fallout-buy-the-dip-or-bail">"HIMS crashes on Novo GLP‑1 fallout: buy‑the‑dip or bail?"</a>, by Surbhi Jain, reports that Hims &amp; Hers Health Inc. (NYSE: HIMS) shares plunged 34% after Novo Nordisk (NYSE: NVO) ended their partnership over claims of unapproved Wegovy compounding, with analysts warning that legal risk and lofty valuation may outweigh oversold technicals.
<a href="https://www.benzinga.com/news/health-care/25/06/46116103/altimmune-stock-sinks-after-mid-stage-data-from-fatty-liver-candidate">"Altimmune stock sinks after mid‑stage data from fatty liver candidate"</a>, by Vandana Singh, reports that Altimmune Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) shares plunged after its Phase 2b trial showed pemvidutide resolved MASH in over half of treated patients (59.1% at 1.2 mg and 52.1% at 1.8 mg) with significant liver‑fat reduction, but missed the fibrosis endpoint — prompting broad investor concern.
<a href="https://www.benzinga.com/news/space/25/06/46055895/ast-spacemobile-stock-downgraded-rocket-lab-prepares-electron-launch-space-stock-countdown">"AST SpaceMobile stock downgraded, Rocket Lab prepares Electron launch: Space stock countdown"</a>, by Erica Kollmann, reports that AST SpaceMobile Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) was downgraded by Scotiabank to Sector Perform with a $45.40 target, even as Rocket Lab Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) gears up for another Electron launch — factors highlighting heightened volatility in space stocks.
For more bearish takes, be sure to see these posts:
<a href="https://www.benzinga.com/markets/earnings/25/06/46083155/aerovironment-stock-sinks-despite-better-than-expected-q4-report-heres-why">AeroVironment Stock Sinks Despite Better-Than-Expected Q4 Report: Here's Why</a>
<a href="https://www.benzinga.com/markets/earnings/25/06/46128371/concentrix-stock-slips-after-mixed-q2-results-details">Concentrix Stock Slips After Mixed Q2 Results: Details</a>
<a href="https://www.benzinga.com/trading-ideas/movers/25/06/46118143/unity-software-stock-is-sliding-today-whats-going-on">Unity Software Stock Is Sliding Today: What's Going On?</a>

Keep up with all the latest breaking news and trading ideas by following <a href="https://twitter.com/Benzinga" target="_blank" rel="noreferrer noopener">Benzinga</a><a href="http://twitter.com/Benzinga" target="_blank" rel="noreferrer noopener"> on X</a>.
Image created using artificial intelligence via Midjourney.

Markets

ASTS

AVAV

CNXC

Hims & Hers Health, Inc. Class A Common Stock

HIMS

MSFT

NVDA

PLTR

PONY

RKLB

Benzinga Bulls And Bears: Nvidia, Micron, HIMS — And Markets Soar On Mideast And Tariff Relief

On Thursday, Altimmune, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) released topline results from the IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-<a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">associated steatohepatitis (MASH)</a>.
MASH is a severe liver disease characterized by fat buildup and inflammation in the liver, which can lead to cirrhosis and liver cancer if untreated.
The Phase 2b trial enrolled 212 participants with biopsy-confirmed MASH and fibrosis stages F2/F3 with and without diabetes randomized 1:2:2 to receive either weekly subcutaneous pemvidutide at 1.2 mg or 1.8 mg doses or placebo for 24 weeks.&nbsp;
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44330443/altimmune-expands-weight-loss-drug-pemvidutides-potential-to-alcohol-related-disorders" rel="noreferrer noopener">Altimmune Expands Weight-Loss Drug Pemvidutide's Potential To Alcohol-Related Disorders</a>
Treatment discontinuation rates were low, with 9% of participants <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/46116103/altimmune-stock-sinks-after-mid-stage-data-from-fatty-liver-candidate" rel="noreferrer noopener">prematurely discontinuing treatment</a>.
In an intent-to-treat (ITT) analysis, the proportions of participants achieving MASH resolution without worsening of fibrosis at 24 weeks were 59.1% and 52.1% for pemvidutide 1.2 mg and 1.8 mg, respectively, versus 19.1% for placebo (p&lt; 0.0001 both doses).
In an ITT analysis, the effects on fibrosis improvement without worsening of MASH were 31.8% and 34.5% for pemvidutide 1.2 mg and 1.8 mg, respectively, compared with 25.9% for placebo (differences not statistically significant).
HC Wainwright reiterated a Buy rating for Altimmune with a price forecast of $12. The firm believes these data support advancing pemvidutide to Phase 3 and strengthens its case as a potential best-in-class therapy. Analyst Patrick R. Trucchio suggested the recent stock price fall was overdone, given expectations for a positive fibrosis outcome at 48 weeks.
Conversely, William Blair maintained a Market Perform rating, citing &#8220;underwhelming&#8221; results. Analyst Andy Hsieh highlighted the lack of statistically significant fibrosis improvement at the 24-week primary endpoint and expressed concerns about demonstrating stringent fibrosis improvement at the 48-week mark since no liver biopsy will be conducted. Hsieh also noted a lack of clear differentiation for pemvidutide in the increasingly competitive MASH market.
Price Action: ALT stock is trading lower by 1.80% to $3.545 at last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/m-a/25/06/46142142/biocryst-just-ditched-its-europe-business-heres-why-investors-are-cheering" target="_blank" rel="noreferrer noopener">BioCryst Just Ditched Its Europe Business — Here&#8217;s Why Investors Are Cheering</a></li>
</ul>
Photo via Shutterstock

Analyst Color

Biotech

News

Health Care

Analyst Ratings

Trading Ideas

General

Altimmune's Fatty Liver Candidate Faces Differentiation Doubts

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Altimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) with a Buy and maintains $12 price target.

Price Target

Reiteration

HC Wainwright & Co. Reiterates Buy on Altimmune, Maintains $12 Price Target

<h3>Gainers</h3>
<ul>
<li>Vor Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VOR#NASDAQ">VOR</a>) shares increased by 93.0% to $1.07 during Thursday's regular session. The company's market cap stands at $69.2 million. </li>
<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) stock increased by 47.03% to $0.36. The company's market cap stands at $3.8 million. </li>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) stock rose 35.26% to $0.33. The market value of their outstanding shares is at $6.6 million. </li>
<li>Kewaunee Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KEQU#NASDAQ">KEQU</a>) stock increased by 30.7% to $52.91. The market value of their outstanding shares is at $115.5 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>Aspire Biopharma Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASBP#NASDAQ">ASBP</a>) stock rose 28.17% to $0.31. The company's market cap stands at $11.8 million. </li>
<li>Synaptogenix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNPX#NASDAQ">SNPX</a>) stock increased by 26.12% to $4.75. The market value of their outstanding shares is at $5.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Altimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) shares declined by 55.4% to $3.44 during Thursday's regular session. The company's market cap stands at $625.3 million. </li>
<li>Reviva Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVPH#NASDAQ">RVPH</a>) stock decreased by 50.51% to $0.38. The company's market cap stands at $35.6 million. </li>
<li>Liminatus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) stock declined by 22.54% to $18.57. The market value of their outstanding shares is at $623.8 million. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) shares declined by 19.81% to $6.29. The company's market cap stands at $4.4 million. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) shares decreased by 17.13% to $7.91. The company's market cap stands at $27.5 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock decreased by 17.1% to $0.03. The company's market cap stands at $12.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ADIL

ASBP

BIAF

EYEN

GCTK

HCTI

KEQU

LIMN

RVPH

SNPX

12 Health Care Stocks Moving In Thursday's Intraday Session

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining over 100 points on Thursday.
The Dow traded up 0.82% to 43,335.29 while the NASDAQ gained 0.69% to 20,110.81. The S&amp;P 500 also rose, gaining, 0.66% to 6,132.29.
Check This Out: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/46113083/amd-taiwan-semiconductor-manufacturing-cnbc-final-trades">AMD, Taiwan Semiconductor And A Financial Stock On CNBC&#8217;s &#8216;Final Trades&#8217;</a>
Leading and Lagging Sectors Materials shares jumped by 0.9% on Thursday.
In trading on Thursday, real estate stocks fell by 1%.
Top Headline
Walgreens Boots Alliance Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) on Thursday reported better-than-expected earnings for the third quarter on Thursday.
The company posted third-quarter sales of $38.99 billion, up 7.2% year over year (+6.9% on constant currency), beating the consensus of $36.84 billion, reflecting sales growth in the U.S. Retail Pharmacy and International segments. Adjusted EPS was 38 cents, down from 63 cents a year ago, beating the consensus of 34 cents, according to data from Benzinga Pro.
Walgreens Boots Alliance withdrew its 2025 guidance as part of the M&amp;A deal with Sycamore Partners. The merger is expected to close in the fourth quarter of calendar year 2025.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Cyngn Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) shares shot up 277% to $18.83 after the company announced it partnered with Nvidia to showcase its autonomous industrial vehicles at Automatica 2025.</li>
<li>Shares of Ascent Solar Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTI#NASDAQ">ASTI</a>) got a boost, surging 113% to $2.4799 after the company entered into a collaborative agreement with NASA.</li>
<li>Worthington Steel, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WS#NYSE">WS</a>) shares were also up, gaining 13% to $29.69 as the company reported stronger-than-expected financial results for the fourth quarter.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Globavend Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GVH#NASDAQ">GVH</a>) shares dropped 74% to $0.1835 after the company announced the pricing of a $15 million offering of 21,739,130 shares at $0.69 per share.</li>
<li>Shares of Altimmune, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) were down 56% to $3.4133 after the company announced topline results from the IMPACT Phase 2b trial of Pemvidutide in the treatment of MASH.</li>
<li>Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVPH#NASDAQ">RVPH</a>) was down, falling 54% to $0.3502 after the company announced a $10 million public offering of 20 million shares and dual warrants at a combined price of $0.50 per share and accompanying warrants.</li>
</ul>
Commodities In commodity news, oil traded up 1.3% to $65.79 while gold traded down 0.2% at $3,335.10.
Silver traded up 0.9% to $36.420 on Thursday, while copper rose 3% to $5.1200.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 rose 0.01%, while Spain's IBEX 35 Index rose 0.03%. London's FTSE 100 rose 0.23%, Germany's DAX 40 gained 0.38% and France's CAC 40 slipped 0.11% during the session.
Asia Pacific Markets
Asian markets closed mixed on Thursday, with Japan's Nikkei gaining 1.65%, Hong Kong's Hang Seng Index falling 0.61%, China's Shanghai Composite falling 0.22% and India's BSE Sensex rising 1.21%.
Economics
<ul class="wp-block-list">
<li>The U.S. economy shrank at an annualized rate of 0.5% in the first quarter, compared to a 0.2% decline as per the second estimate.</li>
<li>U.S. initial jobless claims declined by 10,000 from the previous week to 236,000 in the week ended June 21.</li>
<li>U.S. durable goods orders climbed by 16.4% month-over-month to $343.6 billion in May compared to a revised 6.6% decline in April.</li>
<li>The U.S. trade deficit in goods increased to $96.6 billion in May from $87.0 billion in the previous month, and versus market estimates of an $88.5 billion gap.</li>
<li>The Chicago Fed National Activity Index rose to –0.28 in May compared to a revised reading of –0.36 in April.</li>
<li>U.S. wholesale inventories declined 0.3% month-over-month to $905.4 billion in May following a revised 0.1% gain in April.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/46108846/nike-likely-to-report-lower-q4-earnings-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call">Nike Likely To Report Lower Q4 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a></li>
</ul>
Photo: Shutterstock

Intraday Update

ASTI

Crude Oil Gains Over 1%; Walgreens Posts Upbeat Earnings

WIIM

Altimmune shares are trading lower after the company released topline results from the IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis.

On Thursday, Altimmune, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) released topline results from the IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH).
Treatment discontinuation rates were low, with 9% of participants <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g46111766/altimmune-announces-positive-topline-results-from-the-impact-phase-2b-trial-of-pemvidutide-in-the-" rel="noreferrer noopener">prematurely discontinuing treatment</a>.
In an intent-to-treat (ITT) analysis, the proportions of participants achieving MASH resolution without worsening of fibrosis at 24 weeks were 59.1% and 52.1% for pemvidutide 1.2 mg and 1.8 mg, respectively, versus 19.1% for placebo (p&lt; 0.0001 both doses).
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44330443/altimmune-expands-weight-loss-drug-pemvidutides-potential-to-alcohol-related-disorders" rel="noreferrer noopener">Altimmune Expands Weight-Loss Drug Pemvidutide&#8217;s Potential To Alcohol-Related Disorders</a>
In an ITT analysis, the effects on fibrosis improvement without worsening of MASH were 31.8% and 34.5% for pemvidutide 1.2 mg and 1.8 mg, respectively, compared with 25.9% for placebo (differences not statistically significant).
A supplemental AI-based analysis demonstrated statistically significant reductions in fibrosis, including 30.6% of participants receiving pemvidutide 1.8 mg achieving a 60% or more reduction in fibrosis compared to 8.2% receiving placebo.
Statistically significant changes in well-established non-invasive tests (NITs) of fibrosis were also observed compared with placebo at both doses.
Together, these data suggest strong evidence of pemvidutide&#8217;s anti-fibrotic activity in the MASH population.
At 24 weeks, mean weight loss in pemvidutide-treated participants was 5.0% and 6.2% at the 1.2 mg and 1.8 mg doses, respectively, versus 1.0% in the placebo arm (p&lt; 0.001, both doses).
Pemvidutide also demonstrated favorable safety and tolerability, with 0.0% and 1.2% adverse events (AE) related discontinuations in the pemvidutide 1.2 mg and 1.8 mg groups versus 2.4% in the placebo group, and there were no serious adverse events (SAEs) related to study medication.
25.8% and 24.1% of participants receiving pemvidutide 1.2 mg and 1.8 mg achieved the stringent endpoint of MASH resolution and fibrosis improvement versus 13.5% in participants receiving placebo (differences not significant).
Participants receiving pemvidutide 1.2 mg and 1.8 mg achieved weight loss of 5.0% and 6.2% vs. 1.0% in placebo (p&lt; 0.001), with the trajectory showing no plateauing at 24 weeks.
Liver fat reductions of 58.0% and 62.8% were achieved in participants who received pemvidutide 1.2 mg and 1.8 mg, respectively, vs. 16.2% in placebo participants (p&lt; 0.001, both doses).
AEs leading to treatment discontinuation were 0.0% and 1.2% for pemvidutide 1.2 mg and 1.8 mg, respectively, vs. 2.4% in participants on placebo.
Price Action: ALT stock is trading lower by 59.9% to $3.090 at last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/06/46114286/walgreens-crushes-sales-forecast-but-deeper-retail-troubles-lurk-beneath" target="_blank" rel="noreferrer noopener">Walgreens Crushes Sales Forecast, But Deeper Retail Troubles Lurk Beneath</a></li>
</ul>
Photo via Shutterstock

Altimmune Stock Sinks After Mid-Stage Data From Fatty Liver Candidate

U.S. stocks traded higher this morning, with the Dow Jones index gaining over 200 points on Thursday.
Following the market opening Thursday, the Dow traded up 0.49% to 43,192.54 while the NASDAQ gained 0.36% to 20,045.46. The S&amp;P 500 also rose, gaining, 0.38% to 6,115.14.
Check This Out: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/46113083/amd-taiwan-semiconductor-manufacturing-cnbc-final-trades">AMD, Taiwan Semiconductor And A Financial Stock On CNBC&#8217;s &#8216;Final Trades&#8217;</a>
Leading and Lagging Sectors Materials shares jumped by 0.8% on Thursday.
In trading on Thursday, real estate stocks fell by 0.8%.
Top Headline
The U.S. economy shrank at an annualized rate of 0.5% in the first quarter, compared to a 0.2% decline as per the second estimate.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Cyngn Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) shares shot up 319% to $20.97 after the company announced it partnered with Nvidia to showcase its autonomous industrial vehicles at Automatica 2025.</li>
<li>Shares of Ascent Solar Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTI#NASDAQ">ASTI</a>) got a boost, surging 114% to $2.49 after the company entered into a collaborative agreement with NASA.</li>
<li>Vor Biopharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VOR#NASDAQ">VOR</a>) shares were also up, gaining 49% to $0.8545 after the company announced it signed a global license agreement with Remegen for its autoimmune asset telitacicept.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Globavend Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GVH#NASDAQ">GVH</a>) shares dropped 74% to $0.1835 after the company announced the pricing of a $15 million offering of 21,739,130 shares at $0.69 per share.</li>
<li>Shares of Altimmune, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) were down 60% to $3.1178 after the company announced topline results from the IMPACT Phase 2b trial of Pemvidutide in the treatment of MASH.</li>
<li>Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVPH#NASDAQ">RVPH</a>) was down, falling 53% to $0.3588 after the company announced a $10 million public offering of 20 million shares and dual warrants at a combined price of $0.50 per share and accompanying warrants.</li>
</ul>
Commodities In commodity news, oil traded up 0.9% to $65.51 while gold traded down 0.6% at $3,324.20.
Silver traded up 0.4% to $36.250 on Thursday, while copper rose 2.7% to $5.1080.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 rose 0.01%, while Spain's IBEX 35 Index rose 0.1%. London's FTSE 100 rose 0.3%, Germany's DAX 40 gained 0.4% and France's CAC 40 slipped 0.2% during the session.
Asia Pacific Markets
Asian markets closed mixed on Thursday, with Japan's Nikkei gaining 1.65%, Hong Kong's Hang Seng Index falling 0.61%, China's Shanghai Composite falling 0.22% and India's BSE Sensex rising 1.21%.
Economics
<ul class="wp-block-list">
<li>The U.S. economy shrank at an annualized rate of 0.5% in the first quarter, compared to a 0.2% decline as per the second estimate.</li>
<li>U.S. initial jobless claims declined by 10,000 from the previous week to 236,000 in the week ended June 21.</li>
<li>U.S. durable goods orders climbed by 16.4% month-over-month to $343.6 billion in May compared to a revised 6.6% decline in April.</li>
<li>The U.S. trade deficit in goods increased to $96.6 billion in May from $87.0 billion in the previous month, and versus market estimates of an $88.5 billion gap.</li>
<li>The Chicago Fed National Activity Index rose to –0.28 in May compared to a revised reading of –0.36 in April.</li>
<li>U.S. wholesale inventories declined 0.3% month-over-month to $905.4 billion in May following a revised 0.1% gain in April.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/46108846/nike-likely-to-report-lower-q4-earnings-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call">Nike Likely To Report Lower Q4 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a></li>
</ul>
Photo via Shutterstock

Equities

Eurozone

Commodities

Dow Surges 200 Points; US GDP Contracts 0.5%

Reuters Cites Altimune Exec, Speaking At A Conf Call, Saying  Based On FDA Guidance Reduction Of Mash With High Level Of Statistical Significance Alone Would Be Sufficient For Approval

U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Thursday.
Shares of Altimmune, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) fell sharply in today's pre-market trading after the company announced topline results from the IMPACT Phase 2b trial of Pemvidutide<a href="https://www.benzinga.com/quote/ALT/news"> in the treatment of MASH</a>.
Altimmune shares dipped 61.2% to $2.99 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul class="wp-block-list">
<li>Bit Digital, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTBT#NASDAQ">BTBT</a>) declined 14.9% to $2.0002 in pre-market trading as the company announced the pricing of public offering of its ordinary shares.</li>
<li>XCF Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAFX#NASDAQ">SAFX</a>) fell 8.8% to $2.07 in pre-market trading after surging more than 32% on Wednesday.</li>
<li>Kratos Defense &amp; Security Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTOS#NASDAQ">KTOS</a>) fell 7% to $39.38 in pre-market trading after the company priced its public offering of common stock.</li>
<li>Waldencast plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WALD#NASDAQ">WALD</a>) fell 6.3% to $2.53 in pre-market trading.</li>
<li>Crescent Biopharma, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBIO#NASDAQ">CBIO</a>) shares fell 6.2% to $16.89 in pre-market trading. Stifel, on Wednesday, initiated coverage on the stock with a Buy rating and announced a price target of $28.</li>
<li>UP Fintech Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIGR#NASDAQ">TIGR</a>) fell 3.3% to $9.62 in pre-market trading.</li>
<li>Nokia Oyj (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOK#NYSE">NOK</a>) fell 2.7% to $5.03 in pre-market trading.</li>
</ul>
Now Read This:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46093486/top-2-utilities-stocks-that-may-fall-off-a-cliff-in-q2"> Top 2 Utilities Stocks That May Fall Off A Cliff In Q2</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

BTBT

CBIO

KTOS

SAFX

TIGR

WALD

Altimmune, Bit Digital, Kratos Defense & Security Solutions And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Vor Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VOR#NASDAQ">VOR</a>) shares moved upwards by 105.6% to $1.14 during Thursday's pre-market session. The market value of their outstanding shares is at $69.2 million. </li>
<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) stock rose 56.95% to $0.39. The market value of their outstanding shares is at $3.8 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) shares increased by 27.42% to $0.4. The company's market cap stands at $16.0 million. </li>
<li>Kewaunee Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KEQU#NASDAQ">KEQU</a>) stock increased by 24.5% to $50.4. The company's market cap stands at $115.5 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>Passage Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PASG#NASDAQ">PASG</a>) shares rose 13.46% to $0.37. The company's market cap stands at $20.2 million. </li>
<li>Aspire Biopharma Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASBP#NASDAQ">ASBP</a>) shares rose 13.23% to $0.27. The company's market cap stands at $11.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Altimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) stock declined by 62.6% to $2.88 during Thursday's pre-market session. The market value of their outstanding shares is at $625.3 million. </li>
<li>Reviva Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVPH#NASDAQ">RVPH</a>) stock declined by 31.9% to $0.52. The market value of their outstanding shares is at $35.6 million. </li>
<li>Crescent Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBIO#NASDAQ">CBIO</a>) shares decreased by 15.56% to $15.2. The company's market cap stands at $351.0 million. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) shares fell 14.8% to $6.68. The company's market cap stands at $4.4 million. </li>
<li>Co-Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CODX#NASDAQ">CODX</a>) stock fell 11.26% to $0.25. The company's market cap stands at $9.3 million. </li>
<li>Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) shares declined by 10.43% to $0.67. The company's market cap stands at $14.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CODX

PASG

PSTV

TRIB

12 Health Care Stocks Moving In Thursday's Pre-Market Session

First product candidate to demonstrate significant MASH effects and weight loss at 24 weeks
Trial met its primary endpoint with statistically significant MASH resolution without worsening of fibrosis in up to 59.1% of participants in an ITT analysis
Fibrosis improvement without worsening of MASH in up to 34.5% of participants in an ITT analysis
Supplemental AI-based analysis demonstrated statistically significant reductions in liver fibrosis at 24 weeks
Weight loss of up to 6.2% at 24 weeks with no plateauing
Potentially best-in-class tolerability, with less than 1% treatment discontinuations due to adverse events in pemvidutide-treated participants
Conference call to be held on June 26, 2025 at 8:30 am ET
GAITHERSBURG, Md., June 26, 2025 (GLOBE NEWSWIRE) -- &nbsp;<a href="https://www.globenewswire.com/Tracker?data=YOr6zKCgGqQv3F1roOZpxCdTUklm3pOuPVaxhGdxtVG3jSUzpwhMZKmQoXcfK34GebAUEtaHt8auaaRaQOTAqw==">Altimmune, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced positive topline results from the IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH).
The Phase 2b trial enrolled 212 participants with biopsy-confirmed MASH and fibrosis stages F2/F3 with and without diabetes randomized 1:2:2 to receive either weekly subcutaneous pemvidutide at 1.2 mg or 1.8 mg doses or placebo for 24 weeks. Treatment discontinuation rates were low, with only 9% of participants prematurely discontinuing treatment. In an intent-to-treat (ITT) analysis, in which participants with missing biopsies were considered non-responders, the proportions of participants achieving MASH resolution without worsening of fibrosis at 24 weeks were 59.1% and 52.1% for pemvidutide 1.2 mg and 1.8 mg, respectively versus 19.1% for placebo (p&lt; 0.0001 both doses). The effects on fibrosis improvement without worsening of MASH in an ITT analysis were 31.8% and 34.5% for pemvidutide 1.2 mg and 1.8 mg, respectively compared with 25.9% for placebo (differences not statistically significant). A supplemental AI-based analysis demonstrated statistically significant reductions in fibrosis, including 30.6% of participants receiving pemvidutide 1.8 mg achieving a 60% or more reduction in fibrosis compared to 8.2% receiving placebo (p&lt; 0.001). Statistically significant changes in well-established non-invasive tests (NITs) of fibrosis, including Enhanced Liver Fibrosis score (ELF) and Vibration-Controlled Transient Elastography (VCTE) were also observed compared with placebo at both doses. Together, these data suggest strong evidence of anti-fibrotic activity of pemvidutide in the MASH population. At 24 weeks, mean weight loss in pemvidutide-treated participants was 5.0% and 6.2% at the 1.2 mg and 1.8 mg doses, respectively, versus 1.0% in the placebo arm (p&lt; 0.001, both doses). Pemvidutide also demonstrated favorable safety and tolerability, with 0.0% and 1.2% adverse events (AE) related discontinuations in the pemvidutide 1.2 mg and 1.8 mg groups versus 2.4% in the placebo group, and there were no serious adverse events (SAEs) related to study medication.

Altimmune Announces Topline Results From IMPACT Phase 2b Trial Of Pemvidutide In MASH; Trial Meets "Primary Endpoint With Statistically Significant MASH Resolution Without Worsening Of Fibrosis In Up To 59.1% Of Participants In ITT Analysis"

Shares of Worthington Steel, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WS#NYSE">WS</a>) rose sharply in today's pre-market trading as the company reported <a href="https://www.benzinga.com/quote/WS/earnings">stronger-than-expected financial results for the fourth quarter.</a>
The company reported quarterly earnings of $1.05 per share, which beat the analyst consensus estimate of 82 cents per share.
Worthington Steel shares jumped 15.7% to $30.38 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul class="wp-block-list">
<li>Vor Biopharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VOR#NASDAQ">VOR</a>) surged 105.6% to $1.14 in pre-market trading. Vor Bio and RemeGen signed a global license agreement for autoimmune asset Telitacicept, securing $125 million payment and $175 million private placement.</li>
<li>Adial Pharmaceuticals, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) gained 51.2% to $0.3719 in pre-market trading. Adial Pharmaceuticals shares gained 7% on Wednesday after the company announced it secured AD04 production agreements with Cambrex and Thermo Fisher Scientific ahead of its New Drug Application submission to the FDA for the treatment of Alcohol Use Disorder.</li>
<li>MKDWELL Tech Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKDW#NASDAQ">MKDW</a>) gained 30% to $0.3061 in pre-market trading.</li>
<li>Baird Medical Investment Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDMD#NASDAQ">BDMD</a>) rose 17.5% to $7.80 in pre-market trading after gaining 4% on Wednesday.</li>
<li>KWESST Micro Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KWE#NASDAQ">KWE</a>) jumped 17.4% to $8.50 in pre-market trading after falling 17% on Wednesday.</li>
<li>Beeline Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLNE#NASDAQ">BLNE</a>) climbed 16.6% to $1.54 in pre-market trading after falling 7% on Wednesday.</li>
<li>Nano Labs Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NA#NASDAQ">NA</a>) gained 14.2% to $12.95 in pre-market trading after dipping 24% on Wednesday.</li>
<li>Altimmune, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) rose 12.8% to $8.70 in pre-market trading. Altimmune will announce 24-week data from IMPACT Phase 2b trial of Pemvidutide in MASH treatment on June 26.</li>
<li>MillerKnoll, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLKN#NASDAQ">MLKN</a>) gained 10.7% to $19.50 in pre-market trading after the company reported better-than-expected quarterly EPS and sales.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul class="wp-block-list">
<li>Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVPH#NASDAQ">RVPH</a>) shares tumbled 30.2% to $0.5310 in pre-market trading after the company announced a proposed public offering.</li>
<li>Globavend Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GVH#NASDAQ">GVH</a>) dipped 12.2% to $0.6105 in pre-market trading after dipping 44% on Wednesday.</li>
<li>ZyVersa Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>) fell 10.7% to $0.6335 in pre-market trading. ZyVersa Therapeutics, on Wednesday, announced a share purchase agreement for up to $10 million in partnership with Williamsburg Venture Holdings to fund clinical development of Cholesterol Efflux Mediator&#x2122; VAR 200.</li>
<li>GlucoTrack, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) dipped 9.4% to $7.10 in pre-market trading. Glucotrack shares jumped 26% on Wednesday after the company and OneTwo Analytics presented final results of their first-in-human study for a continuous blood glucose monitor, which met all primary and secondary endpoints.</li>
<li>Wag! Group Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PET#NASDAQ">PET</a>) declined 9% to $0.0975 in pre-market trading after gaining 6% on Wednesday.</li>
<li>XCF Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAFX#NASDAQ">SAFX</a>) fell 8.8% to $2.07 in pre-market trading after surging more than 32% on Wednesday.</li>
<li>Portage Biotech Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) declined 7.5% to $5.65 in pre-market trading. Portage Biotech shares gained 7% on Wednesday after the company announced it regained Nasdaq compliance.</li>
<li>Kratos Defense &amp; Security Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTOS#NASDAQ">KTOS</a>) fell 7% to $39.38 in pre-market trading after the company priced its public offering of common stock.</li>
<li>Crescent Biopharma, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBIO#NASDAQ">CBIO</a>) shares fell 6.2% to $16.89 in pre-market trading. Stifel, on Wednesday, initiated coverage on the stock with a Buy rating and announced a price target of $28.</li>
<li>Oriental Rise Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORIS#NASDAQ">ORIS</a>) fell 5% to $0.5992 in pre-market trading after dipping around 32% on Wednesday.</li>
</ul>
Now Read This:<a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46093486/top-2-utilities-stocks-that-may-fall-off-a-cliff-in-q2"> </a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46093486/top-2-utilities-stocks-that-may-fall-off-a-cliff-in-q2">Top 2 Utilities Stocks That May Fall Off A Cliff In Q2</a> </li>
</ul>
Photo via Shutterstock

BDMD

BLNE

MKDW

MLKN

ORIS

PRTG

ZVSA

Why Worthington Steel Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket

Reported Earlier, Altimmune Set To Announce 24-Week Data From IMPACT Phase 2b Trial Of Pemvidutide In MASH Treatment On June 26, 2025

<a href="https://www.globenewswire.com/Tracker?data=sRJiU6AhBwRs7N2q0k9SUJED5c2NDl4SjhSsHUwYHRP4meEtNPhrehANOUDTP0kRW6urx4bwssPhRWmHGPipsA==">Altimmune, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced an oral presentation and three poster presentations on pemvidutide at the American Diabetes Association's (ADA) 85th Scientific Sessions, to be held in Chicago, IL from June 20-23, 2025. Pemvidutide is a novel, investigational GLP-1/glucagon dual receptor agonist under development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), obesity, alcohol use disorder (AUD) and alcohol-associated liver disease (ALD).
Details for the oral presentation are as follows:
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Session Title:</td>
<td>Early Phase, Post Hoc, and Subgroup Analyses from Clinical Trials Testing Incretin-Based Therapies – Take 1</td>
</tr>
<tr>
<td>Session Date/Time:</td>
<td>Saturday, June 21, 2025, 4:30 PM - 6:00 PM CDT</td>
</tr>
<tr>
<td>Presentation Title:</td>
<td>Effects of Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, on Cardioinflammatory Lipids in Subjects with Obesity or Overweight</td>
</tr>
<tr>
<td>Presenter:</td>
<td>John J. Suschak, Ph.D., Senior Director, Translational Science, Altimmune</td>
</tr>
<tr>
<td>Presentation Date/Time:</td>
<td>Saturday, June 21, 2025 at 5:45 PM CDT</td>
</tr>
</tbody>
</table>
</figure>
 &nbsp;
Details of the poster presentations are as follows:
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Title:</td>
<td>Integrated Analysis Supports Cardiovascular Safety and Risk Reduction with Pemvidutide Treatment (poster #749-P)</td>
</tr>
<tr>
<td>Presenter:</td>
<td>Shaheen Tomah, M.D., Director, Clinical Development, Altimmune</td>
</tr>
<tr>
<td>Presentation Date/Time:</td>
<td>Sunday, June 22, 2025, 12:30 PM - 1:30 PM CDT</td>
</tr>
</tbody>
</table>
</figure>
 &nbsp;
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Title:</td>
<td>Non-invasive Tests of Central Adiposity Correlate with Reductions in MRI-measured Visceral Adipose Tissue Mass in Subjects with Overweight or Obesity Treated with Pemvidutide (poster #748-P)</td>
</tr>
<tr>
<td>Presenter:</td>
<td>Shaheen Tomah, M.D., Director, Clinical Development, Altimmune</td>
</tr>
<tr>
<td>Presentation Date/Time:</td>
<td>Sunday, June 22, 2025, 12:30 PM - 1:30 PM CDT</td>
</tr>
</tbody>
</table>
</figure>
 &nbsp;
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Title:</td>
<td>Pemvidutide, a Balanced GLP-1/Glucagon Dual Receptor Agonist, Enhances Reverse Cholesterol Transport in a Golden Syrian Hamster Model (poster #778-P)</td>
</tr>
<tr>
<td>Presenter:</td>
<td>John J. Suschak, Ph.D., Senior Director, Translational Science, Altimmune</td>
</tr>
<tr>
<td>Presentation Date/Time:</td>
<td>Sunday, June 22, 2025, 12:30PM - 1:30 PM CDT</td>
</tr>
</tbody>
</table>
</figure>
 &nbsp;

Altimmune to Present Data on Obesity and Liver Drug Pemvidutide at Upcoming Diabetes Conference

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/13/25</td>
<td>$55.00</td>
<td>$82.5K</td>
<td>2.3K</td>
<td>4.5K</td>
</tr>
<tr>
<td>LQDA</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>07/18/25</td>
<td>$15.00</td>
<td>$27.9K</td>
<td>723</td>
<td>1.1K</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>08/15/25</td>
<td>$27.50</td>
<td>$26.3K</td>
<td>3.6K</td>
<td>897</td>
</tr>
<tr>
<td>ALT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$6.00</td>
<td>$185.2K</td>
<td>930</td>
<td>783</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/19/25</td>
<td>$350.00</td>
<td>$80.9K</td>
<td>4.1K</td>
<td>712</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$115.00</td>
<td>$45.6K</td>
<td>2.5K</td>
<td>600</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$30.00</td>
<td>$27.2K</td>
<td>14.5K</td>
<td>195</td>
</tr>
<tr>
<td>INSM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$75.00</td>
<td>$70.1K</td>
<td>420</td>
<td>157</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$75.00</td>
<td>$29.0K</td>
<td>1.6K</td>
<td>94</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$770.00</td>
<td>$32.4K</td>
<td>222</td>
<td>87</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we observe a call option sweep with bearish sentiment. It expires in 3 day(s) on June 13, 2025. Parties traded 500 contract(s) at a $55.00 strike. This particular call needed to be split into 67 different trades to become filled. The total cost received by the writing party (or parties) was $82.5K, with a price of $165.0 per contract. There were 2313 open contracts at this strike prior to today, and today 4580 contract(s) were bought and sold. 
• Regarding LQDA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LQDA#NASDAQ">LQDA</a>), we observe a put option trade with neutral sentiment. It expires in 38 day(s) on July 18, 2025. Parties traded 215 contract(s) at a $15.00 strike. The total cost received by the writing party (or parties) was $27.9K, with a price of $130.0 per contract. There were 723 open contracts at this strike prior to today, and today 1174 contract(s) were bought and sold. 
• Regarding VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we observe a call option trade with neutral sentiment. It expires in 66 day(s) on August 15, 2025. Parties traded 40 contract(s) at a $27.50 strike. The total cost received by the writing party (or parties) was $26.3K, with a price of $659.0 per contract. There were 3634 open contracts at this strike prior to today, and today 897 contract(s) were bought and sold. 
• For ALT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>), we notice a put option sweep that happens to be bearish, expiring in 38 day(s) on July 18, 2025. This event was a transfer of 1122 contract(s) at a $6.00 strike. This particular put needed to be split into 62 different trades to become filled. The total cost received by the writing party (or parties) was $185.2K, with a price of $165.0 per contract. There were 930 open contracts at this strike prior to today, and today 783 contract(s) were bought and sold. 
• For UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we notice a call option trade that happens to be neutral, expiring in 192 day(s) on December 19, 2025. This event was a transfer of 40 contract(s) at a $350.00 strike. The total cost received by the writing party (or parties) was $80.9K, with a price of $2023.0 per contract. There were 4181 open contracts at this strike prior to today, and today 712 contract(s) were bought and sold. 
• For MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we notice a call option sweep that happens to be bearish, expiring in 220 day(s) on January 16, 2026. This event was a transfer of 600 contract(s) at a $115.00 strike. This particular call needed to be split into 49 different trades to become filled. The total cost received by the writing party (or parties) was $45.6K, with a price of $76.0 per contract. There were 2577 open contracts at this strike prior to today, and today 600 contract(s) were bought and sold. 
• For MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we notice a put option sweep that happens to be bullish, expiring in 101 day(s) on September 19, 2025. This event was a transfer of 50 contract(s) at a $30.00 strike. This particular put needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $27.2K, with a price of $545.0 per contract. There were 14560 open contracts at this strike prior to today, and today 195 contract(s) were bought and sold. 
• For INSM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>), we notice a call option sweep that happens to be bearish, expiring in 66 day(s) on August 15, 2025. This event was a transfer of 39 contract(s) at a $75.00 strike. This particular call needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $70.1K, with a price of $1806.0 per contract. There were 420 open contracts at this strike prior to today, and today 157 contract(s) were bought and sold. 
• Regarding NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we observe a call option trade with bullish sentiment. It expires in 220 day(s) on January 16, 2026. Parties traded 20 contract(s) at a $75.00 strike. The total cost received by the writing party (or parties) was $29.0K, with a price of $1450.0 per contract. There were 1606 open contracts at this strike prior to today, and today 94 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a put option sweep that happens to be bullish, expiring in 66 day(s) on August 15, 2025. This event was a transfer of 8 contract(s) at a $770.00 strike. This particular put needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $32.4K, with a price of $4055.0 per contract. There were 222 open contracts at this strike prior to today, and today 87 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

INSM

LQDA

MRNA

VKTX

10 Health Care Stocks Whale Activity In Today's Session

Shares of Altimmune Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) rose 5.8% to $5.82 on Tuesday afternoon, despite no new company-specific news for the session. The biotech stock is trending on the social media platform Stocktwits, possibly fueled by high short interest and investor excitement over recent clinical trial developments.
What To Know: On Monday, Altimmune <a href="https://www.benzinga.com/pressreleases/25/05/g45490287/altimmune-announces-initiation-of-reclaim-phase-2-trial-evaluating-the-efficacy-and-safety-of-pemv">announced</a> it has enrolled the first subject in its RECLAIM Phase 2 trial evaluating pemvidutide for Alcohol Use Disorder. Pemvidutide, a dual GLP-1/glucagon receptor agonist, is also being studied for MASH, obesity, and Alcohol-Associated Liver Disease. 
RECLAIM will involve 100 subjects across 15 U.S. sites, with the primary endpoint focused on reducing heavy drinking days over 24 weeks.
According to data from <a href="https://www.benzinga.com/pro/register?gspk=bHVrZWphY29iaTUzNDg&amp;gsxid=8ImWZqfDzlXA">Benzinga Pro</a>, the stock has a short float of 22.58 million shares, representing 28.05% of float, indicating heavy short interest and potential for a short squeeze.
Altimmune's <a href="https://www.benzinga.com/pressreleases/25/05/g45490287/altimmune-announces-initiation-of-reclaim-phase-2-trial-evaluating-the-efficacy-and-safety-of-pemv">ongoing</a> Phase 2b trial in MASH is expected to deliver topline results in the second-quarter, with its ALD trial set to begin enrollment in the third-quarter.
Read Also: <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/05/45521011/short-seller-targets-archer-aviation-stock-extends-wager-to-tonight-show-host-jimmy-fallon-reckless-promotion">Short Seller Targets Archer Aviation Stock, Extends Wager To &#8216;Tonight Show&#8217; Host Jimmy Fallon — &#8216;Reckless&#8217; Promotion</a>
<h2 class="wp-block-heading">How To Buy ALT Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Altimmune&#8217;s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from Benzinga Pro, ALT has a 52-week high of $11.16 and a 52-week low of $3.55.
Photo: Shutterstock

Altimmune (ALT) Stock Rises Amid Clinical Trial Progress: What's Going On?

Altimmune, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has enrolled the first subject in the RECLAIM Phase 2 trial evaluating the efficacy and safety of pemvidutide in subjects with Alcohol Use Disorder (AUD). Pemvidutide is a novel, investigational GLP-1/glucagon dual receptor agonist under development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), obesity, AUD and alcohol liver disease (ALD). IMPACT, a Phase 2b trial of pemvidutide in MASH, is expected to read out topline data in the second quarter of 2025, and a Phase 2 trial of pemvidutide in ALD is expected to initiate enrollment in the third quarter of 2025.
RECLAIM is a randomized, placebo-controlled trial being conducted at approximately 15 sites in the United States, with Dr. Henry Kranzler, Karl E. Rickels Professor of Psychiatry and Director, Center for Studies of Addiction at the University of Pennsylvania Perelman School of Medicine, serving as the Principal Investigator. The trial is expected to enroll approximately 100 subjects randomized 1:1 to receive either 2.4 mg pemvidutide or placebo weekly for 24 weeks. The primary endpoint of the trial is a change in alcohol consumption, assessed as the change from baseline in the average number of heavy drinking days per week at Week 24, with the key secondary endpoints including the proportion of subjects achieving a 2-level reduction in World Health Organization (WHO) risk drinking level and the absolute change from baseline in average levels of phosphatidylethanol (PEth), a serum biomarker of alcohol intake. An investigational new drug (IND) application for pemvidutide in AUD was filed in December 2024 and was cleared by FDA in January 2025.

Altimmune Begins Phase 2 Trial of Pemvidutide for Alcohol Use Disorder With First Patient Enrolled

Under the terms of the agreement, $15 million will be drawn at closing. An additional $25 million is available in 2025 at Altimmune's option, subject to certain clinical and financial milestones. The remaining $60 million is available beginning in 2026, with $15 million subject to the achievement of certain clinical and financial milestones and up to $45 million available subject to the approval of Hercules. The facility is structured as interest only for the first 24 months, extendable up to 42 months on achievement of milestones. The loan matures 48 months from closing, and no warrants are included in the agreement.
 &nbsp;

Financing

Altimmune Secures Up To $100M In Credit Facility From Hercules Capital

Altimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.36) by 27.78 percent. This is a 23.53 percent increase over losses of $(0.34) per share from the same period last year. The company reported $5.00 thousand in sales this quarter. This is the same as the same period last year.

Comments

Altimmune

Altimmune (ALT) Options

Altimmune (NASDAQ:ALT) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL